Pazopanib vs. Pazopanib plus Gemcitabine in patients with relapsed or metastatic uterine leiomyosarcomas or uterine carcinosarcomas: a multi-center, randomized phase-II clinical trial of the NOGGO and AGO.
Phase of Trial: Phase II
Latest Information Update: 11 Jul 2019
Price : $35 *
At a glance
- Drugs Pazopanib (Primary) ; Gemcitabine
- Indications Carcinoma; Leiomyosarcoma; Sarcoma; Uterine cancer
- Focus Therapeutic Use
- Acronyms PazoDoble
- 08 Jul 2019 Planned End Date changed from 1 Jun 2016 to 1 Dec 2023.
- 08 Jul 2019 Planned primary completion date changed from 1 Mar 2015 to 1 Dec 2022.
- 10 Jan 2014 New trial record